These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28230457)

  • 1. Comparative Effectiveness of Rapid-Acting Insulins in Adults with Diabetes.
    Racsa PN; Meah Y; Ellis JJ; Saverno KR
    J Manag Care Spec Pharm; 2017 Mar; 23(3):291-298. PubMed ID: 28230457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
    Rascati KL; Worley K; Meah Y; Everhart D
    J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial.
    Grabner M; Chu J; Raparla S; Quimbo R; Zhou S; Conoshenti J
    Postgrad Med; 2013 May; 125(3):204-13. PubMed ID: 23748521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Retrospective Database Study Comparing Diabetes-Related Medication Adherence and Health Outcomes for Mail-Order Versus Community Pharmacy.
    Schwab P; Racsa P; Rascati K; Mourer M; Meah Y; Worley K
    J Manag Care Spec Pharm; 2019 Mar; 25(3):332-340. PubMed ID: 30816817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting.
    Davis SN; Wei W; Garg S
    Endocr Pract; 2011; 17(6):845-52. PubMed ID: 21550952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials.
    Asche CV; Luo W; Aagren M
    Curr Med Res Opin; 2013 Oct; 29(10):1287-96. PubMed ID: 23865725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007; 29 Spec No():1294-305. PubMed ID: 18046929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics Relating to Adherence and Persistence to Basal Insulin Regimens Among Elderly Insulin-Naïve Patients with Type 2 Diabetes: Pre-Filled Pens versus Vials/Syringes.
    Slabaugh SL; Bouchard JR; Li Y; Baltz JC; Meah YA; Moretz DC
    Adv Ther; 2015 Dec; 32(12):1206-21. PubMed ID: 26563324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
    Bibeau WS; Fu H; Taylor AD; Kwan AY
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
    Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.
    Russell-Jones D; Heller SR; Buchs S; Sandberg A; Valentine WJ; Hunt B
    Diabetes Obes Metab; 2017 Dec; 19(12):1773-1780. PubMed ID: 28573681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis.
    Andrade-Castellanos CA; Colunga-Lozano LE; Delgado-Figueroa N; Gonzalez-Padilla DA
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011281. PubMed ID: 26798030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
    Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
    Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus.
    Kent DJ; McMahill-Walraven CN; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1162-1171. PubMed ID: 31405345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.
    Ayyagari R; Wei W; Cheng D; Pan C; Signorovitch J; Wu EQ
    Value Health; 2015 Mar; 18(2):198-205. PubMed ID: 25773555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
    Raval AD; Nguyen MH; Zhou S; Grabner M; Barron J; Quimbo R
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Weight Change, Clinical Outcomes, and Health Care Costs in Patients with Type 2 Diabetes.
    Mukherjee J; Sternhufvud C; Smith N; Bell K; Stott-Miller M; McMorrow D; Johnston S
    J Manag Care Spec Pharm; 2016 May; 22(5):449-66. PubMed ID: 27123909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
    Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
    J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.